Inogen (NASDAQ: INGN) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its rivals? We will compare Inogen to related companies based on the strength of its dividends, valuation, earnings, profitability, risk, institutional ownership and analyst recommendations.

Volatility & Risk

Inogen has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Inogen’s rivals have a beta of 1.06, suggesting that their average share price is 6% more volatile than the S&P 500.

Institutional and Insider Ownership

63.1% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 5.3% of Inogen shares are owned by company insiders. Comparatively, 12.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Inogen and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Inogen $221.89 million $36.52 million 89.10
Inogen Competitors $827.23 million $159.49 million 36.41

Inogen’s rivals have higher revenue and earnings than Inogen. Inogen is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations and price targets for Inogen and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inogen 0 3 2 0 2.40
Inogen Competitors 326 1499 2619 105 2.55

Inogen currently has a consensus target price of $90.80, suggesting a potential downside of 3.85%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.69%. Given Inogen’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Inogen has less favorable growth aspects than its rivals.


This table compares Inogen and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inogen 10.36% 12.45% 10.36%
Inogen Competitors -127.09% -36.26% -10.19%


Inogen rivals beat Inogen on 9 of the 13 factors compared.

About Inogen

Inogen, Inc. is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device. Its three portable product offerings, the Inogen One G4, Inogen One G3 and Inogen One G2, at approximately 2.8, 4.8 and 7.0 pounds with a single battery, respectively. Its Inogen One G4, Inogen One G3 and Inogen One G2 are sub-3, sub-5 and sub-10 pound portable oxygen concentrators, respectively. All of its Inogen One systems are equipped with Intelligent Delivery Technology. The Inogen At Home stationary oxygen concentrator allows it to access the non-ambulatory oxygen patient market and serves as a backup to its Inogen One system for ambulatory patients on its rental service.

Receive News & Stock Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related stocks with our FREE daily email newsletter.